4. Discussion
left ventricular dysfunction, malignant hemopathies, myocardial deformation
LEFT VENTRICULAR DYSFUNCTION
We performed a prospective, randomised, open-label clinical trial to evaluate the use of ivabradine for the primary prevention of anthracycline-induced cardiotoxicity. Our study is the first to investigate ivabradine’s cardioprotective properties and provide a comprehensive analysis of changes in cardiac biomarkers and echocardiographic parameters during anthracycline-based chemotherapy. The cardioprotective effects of ivabradine may be explained by the pleiotropic effects. It reduces heart rate without affecting myocardial inotropic function, reducing oxygen demand and maintaining diastolic time. As a result, it reduces myocardial stress and may improve myocardial deformation and coronary microcirculation following anthracycline exposure [We compared our results with four major trials that examined the cardioprotective effects of ACEIs and BBs on anthracycline-induced cardiopathy: OVERCOME (“Prevention of left ventricular dysfunction with enalapril and carvedilol in patients submitted to intensive chemotherapy for the treatment of malignant hemopathies”) [